Gabapentin Tablet, Film Coated
Product Images NDC 71610-044

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71610-044). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71610 0044 30

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

Figure 1 (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)
This is a formula for calculating the estimated creatinine clearance (CLOr) for patients based on their age, weight, and serum creatinine level. The formula includes an adjustment factor of 0.85 for female patients.*
FDA Label Image

Chem Structure (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

FDA Label Image

Figure01 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

FDA Label Image

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

Figure02 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)
This appears to be a chart or table related to pain scores for a fixed dose period of four weeks, possibly related to a medication trial. The chart includes two dose levels of gabapentin and a placebo group, with the mean pain score recorded for each week. It is not clear what the unit of measurement is for the pain scores, or what specific type of pain is being studied.*
FDA Label Image

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

Figure03 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)
The text describes the proportion of responders in controlled PHN Studies on the basis of patients with > 50% reduction in pain score. The details are provided in Figure 3. There are two studies- Study 1 and Study 2. The response rates for the patients in Study 1 and Study 2 are 32% and 34% respectively. The text also includes costs in GBP-GBP 3600 for the study drug, GBP 1800 for placebo, and GBP 2400 for an unknown item.*
FDA Label Image

Figure4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.